Emmelie Cansby

Emmelie Cansby

Auto-generated profile, based on publicly available information

Emmelie Cansby

Department of Chemistry and Molecular Biology, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
ANAnnika Nerstedt
Annika Nerstedt
YKYeshwant Kurhe
Yeshwant Kurhe
ECEmmelie Cansby
Emmelie Cansby
MCMara Caputo
Mara Caputo
LGLei Gao
Lei Gao
MMMargit Mahlapuu
Margit Mahlapuu
Annika Nerstedt, Yeshwant Kurhe, Emmelie Cansby, Mara Caputo, Lei Gao, Egor Vorontsov, Marcus Stahlman, Esther Nuñez-Durán, Jan Boren, Hanns-Ulrich Marschall, Douglas G Mashek, Darren N. Saunders, Carina Sihlbom, Andrew J. Hoy, Margit Mahlapuu

6 June 2022 in Journal of Lipid Research
Verified
Journal Article
Open access
SASumit Kumar Anand
Sumit Kumar Anand
MCMara Caputo
Mara Caputo
YXYing Xia
Ying Xia
EAEmma Andersson
Emma Andersson
ECEmmelie Cansby
Emmelie Cansby
MMMargit Mahlapuu
Margit Mahlapuu
The primary hepatic consequence of obesity is non-alcoholic fatty liver disease (NAFLD), affecting about 25% of the global adult population. Non-alcoholic steatohepatitis (NASH) is a severe form of NAFLD characterized by liver lipid accumulation, inflammation, and hepatocyte ballooning, with a different degree of hepatic fibrosis. In the light of rapidly increasing prevalence of NAFLD and NASH, there is an urgent need for improved understanding of the molecular pathogenesis of these diseases. The aim of this study was to decipher the possible role of STE20-type kinase MAP4K4 in the regulation of hepatocellular lipotoxicity and susceptibility to NAFLD. We found that MAP4K4 mRNA expression in human liver biopsies was positively correlated with key hallmarks of NAFLD (i.e., liver steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis). We also found that the silencing of MAP4K4 suppressed lipid deposition in human hepatocytes by stimulating β-oxidation and triacylglycerol secretion, while attenuating fatty acid influx and lipid synthesis. Furthermore, downregulation of MAP4K4 markedly reduced the glycolysis rate and lowered incidences of oxidative/endoplasmic reticulum stress. In parallel, we observed suppressed JNK and ERK and increased AKT phosphorylation in MAP4K4-deficient hepatocytes. Together, these results provide the first experimental evidence supporting the potential involvement of STE20-type kinase MAP4K4 as a component of the hepatocellular lipotoxic milieu promoting NAFLD susceptibility.

25 July 2023 in The FASEB Journal
Verified
Journal Article
Open access
MCMara Caputo
Mara Caputo
YXYing Xia
Ying Xia
SASumit Kumar Anand
Sumit Kumar Anand
ECEmmelie Cansby
Emmelie Cansby
EAEmma Andersson
Emma Andersson
MMMargit Mahlapuu
Margit Mahlapuu
Hepatocellular carcinoma (HCC) is one of the most fatal and fastest growing malignancies. Recently, nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation, cell injury (hepatocyte ballooning), and different stages of fibrosis, has emerged as a major catalyst for HCC. Because the STE20‐type kinases, MST3 and MST4, have been described as critical molecular regulators of NASH pathophysiology, we here focused on determining the relevance of these proteins in human HCC. By analyzing public datasets and in‐house cohorts, we found that hepatic MST3 and MST4 expression was positively correlated with the incidence and severity of HCC. We also found that the silencing of both MST3 and MST4, but also either of them individually, markedly suppressed the tumorigenesis of human HCC cells including attenuated proliferation, migration, invasion, and epithelial‐mesenchymal transition. Mechanistic investigations revealed lower activation of STAT3 signaling in MST3/MST4‐deficient hepatocytes and identified GOLGA2 and STRIPAK complex as the binding partners of both MST3 and MST4. These findings reveal that MST3 and MST4 play a critical role in promoting the progression of HCC and suggest that targeting these kinases may provide a novel strategy for the treatment of liver cancer.

10 October 2024 in Journal of Lipid Research
Verified
Journal Article
Open access
ECEmmelie Cansby
Emmelie Cansby
MCMara Caputo
Mara Caputo
EAEmma Andersson
Emma Andersson
RSRasool Saghaleyni
Rasool Saghaleyni
MHMarcus Henricsson
Marcus Henricsson
MMMargit Mahlapuu
Margit Mahlapuu
Metabolic dysfunction-associated steatotic liver disease has emerged as a leading global cause of chronic liver disease. Our recent translational investigations have shown that the STE20-type kinases comprising the GCKIII subfamily-MST3, STK25, and MST4-associate with hepatic lipid droplets and regulate ectopic fat storage in the liver; however, the mode of action of these proteins remains to be resolved. By comparing different combinations of the silencing of MST3, STK25, and/or MST4 in immortalized human hepatocytes, we found that their single knockdown results in a similar reduction in hepatocellular lipid content and metabolic stress, without any additive or synergistic effects observed when all three kinases are simultaneously depleted. A genome-wide yeast two-hybrid screen of the human hepatocyte library identified several interaction partners contributing to the GCKIII-mediated regulation of liver lipid homeostasis, that is, PDCD10 that protects MST3, STK25, and MST4 from degradation, MAP4K4 that regulates their activity via phosphorylation, and HSD17B11 that controls their action via a conformational change. Finally, using in vitro kinase assays on microfluidic microarrays, we pinpointed various downstream targets that are phosphorylated by the GCKIII kinases, with known functions in lipogenesis, lipolysis, and lipid secretion, as well as glucose uptake, glycolysis, hexosamine synthesis, and ubiquitination. Together, this study demonstrates that the members of the GCKIII kinase subfamily regulate hepatocyte lipid metabolism via common pathways. The results shed new light on the role of MST3, STK25, and MST4, as well as their interactions with PDCD10, MAP4K4, and HSD17B11, in the control of liver lipid homeostasis and metabolic dysfunction-associated steatotic liver disease susceptibility.

19 April 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
ECEmmelie Cansby
Emmelie Cansby
SKSima Kumari
Sima Kumari
MCMara Caputo
Mara Caputo
YXYing Xia
Ying Xia
RPRando Porosk
Rando Porosk
MMMargit Mahlapuu
Margit Mahlapuu
Recent studies highlight the importance of lipotoxic damage in aortic cells as the major pathogenetic contributor to atherosclerotic disease. Since the STE20-type kinase STK25 has been shown to exacerbate ectopic lipid storage and associated cell injury in several metabolic organs, we here investigate its role in the main cell types of vasculature. We depleted STK25 by small interfering RNA in human aortic endothelial and smooth muscle cells exposed to oleic acid and oxidized LDL. In both cell types, the silencing of STK25 reduces lipid accumulation and suppresses activation of inflammatory and fibrotic pathways as well as lowering oxidative and endoplasmic reticulum stress. Notably, in smooth muscle cells, STK25 inactivation hinders the shift from a contractile to a synthetic phenotype. Together, we provide several lines of evidence that antagonizing STK25 signaling in human aortic endothelial and smooth muscle cells is atheroprotective, highlighting this kinase as a new potential therapeutic target for atherosclerotic disease.